The FDA approved Celcuity’s cancer therapy Revtorpyk, clearing the company’s first-in-class effort in a common breast-cancer setting. Reporting also highlighted that Wall Street didn’t expect delays around commercial rollout timing, with the drug expected to take until late-quarter to launch. The approval comes as Celcuity seeks to convert regulatory momentum into market access and uptake among oncologists and payers. The company’s stock reaction suggested investors were focused on execution details beyond clearance. For the sector, the episode underlines how approval-to-launch timelines can influence trading and near-term commercialization optics—even when the regulatory milestone itself is achieved.